Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 5/20 | 0.61 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.50 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.48 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CDA | P32320 | 1/20 | 0.45 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL432297 | 1.00 | P2RY6 (0.61) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL881950 | 1.00 | P2RY6 (0.61) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL432298 | 1.00 | P2RY6 (0.61) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL22972654 | 0.94 | P2RY6 (0.55) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL31160212 | 0.93 | P2RY6 (0.61) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL16904894 | 0.93 | P2RY6 (0.61) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL31160188 | 0.93 | P2RY6 (0.61) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL18852530 | 0.92 | P2RY6 (0.70) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL565905 | 0.92 | P2RY6 (0.70) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL16805383 | 0.92 | P2RY6 (0.70) | P2RY6P2RY14NT5EABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 698 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2270024-B1 | Antisense modulation of superoxide dismutase 1, soluble expression | IONIS PHARMACEUTICALS INC (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20180094260-A1 | EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS | KASTLE THERAPEUTICS, LLC (US) | 2018-04-05 | — | — | US | disclosed |
| US-20170355986-A1 | ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION | KASTLE THERAPEUTICS, LLC (US) | 2017-12-14 | — | — | US | disclosed |
| US-9476051-B2 | Antisense modulation of superoxide dismutase 1, soluble expression | IONIS PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| WO-2016033424-A1 | METHODS FOR THE PREVENTION AND TREATMENT OF MAJOR ADVERSE CARDIOVASCULAR EVENTS USING COMPOUNDS THAT MODULATE APOLIPOPROTEIN B | GENZYME CORPORATION (US) | 2016-03-03 | — | — | WO | disclosed |
| US-20150232838-A1 | EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS | COMERICA BANK | 2015-08-20 | — | — | US | disclosed |
| US-20150167008-A1 | ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| EP-2365094-B1 | Antisense modulation of PTP1B expression | ISIS PHARMACEUTICALS INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-20150105440-A1 | ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION | GENZYME CORPORATION (US) | 2015-04-16 | — | — | US | disclosed |
| EP-2174945-B1 | Antisense modulation of apolipoprotein B expression | GENZYME CORP (US) | 2015-04-08 | — | — | EP | disclosed |
| US-5962672-A | OLIGONUCLEOTIDES AGAINST NUCLEIC ACID WHICH CODES FOR SMALL GUANOSINE TRIPHOSPHATASE IMPORTANT IN REGULATION OF CYTOSKELETON DURING CELL CYCLE; FOR ANTICARCINOGENIC/ANTITUMOR AGENTS | ISIS PHARMACEUTICALS INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5962671-A | OLIGONUCLEOTIDE WHICH SUPPRESSES GENE EXPRESSION OF FACTOR ASSOCIATED WITH NEUTRAL SPHINGOMYELINASE ACTIVATION; FACTOR IS IS A MEDIATOR OF TUMOR NECROSIS FACTOR ACTIVATION OF THAT ENZYME THROUGH A SIGNAL TRANSDUCTION PATHWAY; GENE THERAPY | ISIS PHARMACEUTICALS INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5962673-A | ANTISENSE AGENT 8 TO 30 NUCLEOBASES IN LENGTH; FOR DIAGNOSIS AND TREATMENT OF ASTHMA, MYASTHENIA GRAVIS, GRAVES' DISEASE, ALLOGRAFT REJECTION, PSORIASIS AND OTHERS; ANTITUMOR/ ANTIPROLIFERATIVE/ANTIDIABETIC/ANTIARTHRITIC AGENTS | ISIS PHARMACEUTICALS INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5959097-A | OLIGONUCLEOTIDE OF 8 TO 30 NUCLEOTIDES WHICH SUPPRESSES EXPRESSION OF SIGNAL TRANSDUCTION KINASE; FOR TREATMENT OF INFECTIONS; ANTIINFLAMMATORY/ANTITUMOR AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5958771-A | OLIGONUCLEOTIDE FROM 8 TO 30 NUCLEOTIDES IN LENGTH; FOR DIAGNOSIS AND THERAPY; ANTITUMOR/ANTIINFLAMMATORY AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5958772-A | TARGETS TO NUCLEIC ACID MOLECULE ENCODING HUMAN CELLULAR INHIBITORS OF APOTOPSIS-1 | ISIS PHARMACEUTICALS INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5958773-A | ANTISENSE COMPOUND 8 TO 30 NUCLEOTIDES IN LENGTH TARGETED TO A NUCLEIC ACID ENCODING HUMAN AKT-1, OF THE SERINE/THREONINE KINASE FAMILY INVOLVED IN SIGNALLING PATHWAYS; INHIBITING EXPRESSION OF AKT-1 WITH THE ANTISENSE COMPOUND | ISIS PHARMACEUTICALS INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5951455-A | OLIGONUCLEOTIDES, TARGETED TO NUCLEIC ACIDS WITH MODULATION AND EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5948680-A | ANTISENSE OLIGONUCLEOTIDE TARGETED TO NUCLEIC ACIDS ENCODING ELK-1; ANTIPROLIFERATIVE AGENTS | ISIS PHARMACEUTICALS INC. (US) | 1999-09-07 | — | — | US | disclosed |
| US-5945290-A | OLIGONUCLEOTIDES TARGETED AGAINST SPECIFIC NUCLEIC ACIDS; FOR ANTITUMOR/ANTICARCINOGENIC AGENTS; DIAGNOSIS AND THERAPY OF RELATED DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 1999-08-31 | — | — | US | disclosed |